[Correlations of HER-2, PCNA, Bcl-2, and Bax expression to prognosis of breast cancer].
OBJECTIVE
Identifying breast cancer patients with high risk and treating them with relevant treatments is a key to improve their survival. This study was to investigate the correlations of human epidermal receptor-2 (HER-2), proliferating cell nuclear antigen (PCNA), Bcl-2, and Bax expression to the prognosis of breast cancer.


METHODS
The expression of HER-2, PCNA, Bcl-2, and Bax in 50 specimens of breast cancer was detected by immunohistochemistry with EnVision staining. Their correlations to the survival time of the patients were analyzed.


RESULTS
The positive rates of HER-2, PCNA, Bcl-2, and Bax in breast cancer tissues were 44.0%, 82.0%, 48.0% and 54.0%, respectively. The median survival for the patients was 62 months, and the 5-year overall survival rate and disease-free survival rate were 82.0% and 38.0%, respectively. Univariate survival analysis suggested that HER-2 and Bax had significant influence on tumor recurrence (P< 0.001). Cox multivariate analysis indicated that the expression of HER-2 and Bax were correlated to regional recurrence and distant metastasis (P < 0.05 and P < 0.01), and Bcl-2 and Bax proteins were independent predictors of overall survival (P < 0.05).


CONCLUSIONS
HER-2 and Bax are related to poor prognosis of breast cancer, while Bcl-2 is related to good prognosis.
Yang
Li
L
Department of Oncology, Affiliated Hospital, Guiyang Medical College, Guiyang, Guizhou, 550004, P. R. China.
Zhu
Xia
X
Ran
Li
L
D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000378:metabolism* / Q000473:pathology; D018270:Carcinoma, Ductal, Breast / Q000378:metabolism / Q000473:pathology; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007150:Immunohistochemistry; D008207:Lymphatic Metastasis; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D018809:Proliferating Cell Nuclear Antigen / Q000378:metabolism*; D016016:Proportional Hazards Models; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D015996:Survival Rate; D051028:bcl-2-Associated X Protein / Q000378:metabolism*
D018809:Proliferating Cell Nuclear Antigen; D019253:Proto-Oncogene Proteins c-bcl-2; D018719:Erb-b2 Receptor Tyrosine Kinases; D051028:bcl-2-Associated X Protein; C508053:ERBB2 protein, human